4884

Kringle Pharma,Inc.

クリングルファーマ株式会社
Healthcare · Biotechnology
Kringle Pharma, Inc. engages in research and develops therapeutic agents for the treatment of intractable diseases in Japan. The company develops HGF products for the treatment of acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scar, and acute kidney injury. Kringle Pharma, Inc. was incorporated in 2001 and is based in Kita, Japan.
← Companies
Price
¥393
Market Cap
¥2.8B
Ent. Value
—
Net Cash est
—
Shares Out.
7.0M
P / E
—
EV / EBIT
—
P / Book
2.16×
P / NCAV
2.15×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥72M ¥80M ¥69M ¥392M ¥290M
Gross Profit ¥72M ¥80M ¥69M ¥303M ¥218M
SG&A ¥982M ¥898M ¥958M ¥730M ¥576M
Operating Income ¥-909M ¥-818M ¥-889M ¥-426M ¥-358M
Non-Operating Income ¥2M ¥63M ¥43M ¥104M ¥82M
Interest Income ¥0M ¥0M ¥0M ¥0M ¥0M
Non-Operating Expenses ¥7M — ¥7M ¥8M ¥24M
Ordinary Income ¥-915M ¥-755M ¥-853M ¥-330M ¥-300M
Pre-tax Income ¥-915M ¥-755M ¥-853M ¥-330M ¥-300M
Income Taxes ¥2M ¥1M ¥1M ¥1M ¥1M
Current Tax ¥2M ¥1M ¥1M ¥1M ¥1M
Net Income (owners) ¥-916M ¥-756M ¥-854M ¥-332M ¥-301M
EPS ¥-133.92 ¥-118.21 ¥-158.46 ¥-68.33 ¥-72.51
Shares Outstanding 7.0M 6.8M 5.5M 5.4M 4.3M
Shares Issued (total) 7.0M 6.8M 5.5M 5.4M 4.3M